Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30482609 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CASP3SENP8SENP7SENP6 | |
| SCHEMBL3468181 | 0.86 | SRD5A2 (0.50) | ALDH1A1CASP3SENP8SENP7SENP6 | |
| SCHEMBL29740498 | 0.85 | ALDH1A1 (0.50) | ALDH1A1MAPTPOLBHPGDCYP1A2 | |
| SCHEMBL1457582 | 0.85 | ALDH1A1 (0.50) | ALDH1A1MAPTKMT2APOLBHPGD | |
| SCHEMBL2637828 | 0.85 | ALDH1A1 (0.50) | ALDH1A1MAPTPOLBHPGDCYP1A2 | |
| SCHEMBL499767 | 0.85 | MAPT (0.67) | ALDH1A1MAPTMAPK1KMT2APOLB | |
| SCHEMBL27751160 | 0.84 | MAPT (0.67) | ALDH1A1MAPTMAPK1POLBHPGD | |
| SCHEMBL612249 | 0.82 | MAPK1 (0.62) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| SCHEMBL499583 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MAPTPOLBHPGDCYP1A2 | |
| SCHEMBL6442538 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MAPTMAPK1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118619823-A | Preparation method of 4-bromo-1-chloro-2- (4- (2-cyclopropyloxy ethoxy) benzyl) benzene | 杭州科巢生物科技有限公司 | 2024-09-10 | — | — | CN | claimed |
| CN-116354799-A | Preparation method of dapagliflozin intermediate | 江苏阿尔法药业股份有限公司 | 2023-06-30 | — | — | CN | claimed |
| CN-116262690-A | Synthesis method of (5-bromo-2-chlorophenyl) (4-ethoxyphenyl) methanone | 苏州小栗医药科技有限公司 | 2023-06-16 | — | — | CN | claimed |
| CN-118619823-A | Preparation method of 4-bromo-1-chloro-2- (4- (2-cyclopropyloxy ethoxy) benzyl) benzene | 杭州科巢生物科技有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-116354799-A | Preparation method of dapagliflozin intermediate | 江苏阿尔法药业股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116354799-A | Preparation method of dapagliflozin intermediate | 江苏阿尔法药业股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116262690-A | Synthesis method of (5-bromo-2-chlorophenyl) (4-ethoxyphenyl) methanone | 苏州小栗医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-2703396-B1 | INHIBITOR OF SODIUM-DEPENDENT GLUCOSE TRANSPORT PROTEIN AND PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING PRELUDE PHARM SCI & TECH CO LTD (CN) | 2016-06-22 | — | — | EP | disclosed |
| EP-2703396-B1 | INHIBITOR OF SODIUM-DEPENDENT GLUCOSE TRANSPORT PROTEIN AND PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING PRELUDE PHARM SCI & TECH CO LTD (CN) | 2016-06-22 | — | — | EP | disclosed |
| US-8957033-B2 | Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof | BEIJING PRELUDE PHARM. SCI. & TECH. CO., LTD. (CN) | 2015-02-17 | — | — | US | disclosed |
| US-8957033-B2 | Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof | BEIJING PRELUDE PHARM. SCI. & TECH. CO., LTD. (CN) | 2015-02-17 | — | — | US | disclosed |
| US-8957033-B2 | Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof | BEIJING PRELUDE PHARM. SCI. & TECH. CO., LTD. (CN) | 2015-02-17 | — | — | US | disclosed |
| EP-2703396-A1 | INHIBITOR OF SODIUM-DEPENDENT GLUCOSE TRANSPORT PROTEIN AND PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Prelude Pharm. Sci.& Tech. Co., Ltd. (CN) | 2014-03-05 | — | — | EP | disclosed |
| EP-2703396-A1 | INHIBITOR OF SODIUM-DEPENDENT GLUCOSE TRANSPORT PROTEIN AND PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Prelude Pharm. Sci.& Tech. Co., Ltd. (CN) | 2014-03-05 | — | — | EP | disclosed |
| US-20140051648-A1 | Inhibitor of Sodium-Dependent Glucose Transport Protein and Preparation Method Therefor and Use Thereof | BEIJING PRELUDE PHARM. SCI. & TECH. CO., LTD. (CN) | 2014-02-20 | — | — | US | disclosed |
| US-20140051648-A1 | Inhibitor of Sodium-Dependent Glucose Transport Protein and Preparation Method Therefor and Use Thereof | BEIJING PRELUDE PHARM. SCI. & TECH. CO., LTD. (CN) | 2014-02-20 | — | — | US | disclosed |
| US-20140051648-A1 | Inhibitor of Sodium-Dependent Glucose Transport Protein and Preparation Method Therefor and Use Thereof | BEIJING PRELUDE PHARM. SCI. & TECH. CO., LTD. (CN) | 2014-02-20 | — | — | US | disclosed |
| WO-2012025857-A1 | CYCLOALKYL METHOXYBENZYL PHENYL PYRAN DERIVATIVES AS SODIUM DEPENDENT GLUCOSE CO TRANSPORTER (SGLT2) INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012025857-A1 | CYCLOALKYL METHOXYBENZYL PHENYL PYRAN DERIVATIVES AS SODIUM DEPENDENT GLUCOSE CO TRANSPORTER (SGLT2) INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051648-A1 | Inhibitor of Sodium-Dependent Glucose Transport Protein and Preparation Method Therefor and Use Thereof | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 1948/4885CASP3 3483/4885SENP8 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.